Owen Jones

Owen Jones

Auto-generated profile, based on publicly available information

Owen Jones

HPB & Multi-Organ Transplant Program, Division of General Surgery, Ajmera Transplant Centre, University Health Network, Toronto, Canada

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2024 in JHEP Reports
Verified
Journal Article
Open access
ZLZhihao Li
Zhihao Li
DADaniel Aliseda
Daniel Aliseda
OJOwen Jones
Owen Jones
LRLuckshi Rajendran
Luckshi Rajendran
CMChristian Tibor Josef Magyar
Christian Tibor Josef Magyar
Arndt VogelArndt Vogel
Arndt Vogel
Gemcitabine/cisplatin (GemCis) was the long-standing first-line treatment for advanced biliary tract cancers (BTCs). Following positive results from the TOPAZ-01 and KEYNOTE-966 trials, immune checkpoint inhibitors (ICIs) combined with chemotherapy are now the standard of care. We aim to compare the efficacy of first-line therapies for advanced BTCs. Our systematic review included studies from five databases focusing on English-language articles published between January 2010 and June 2024. We included randomized clinical trials (RCTs) that featured GemCis in a treatment arm for treatment-naive adults with advanced BTCs. The primary endpoints were overall survival (OS) and progression-free survival. We conducted a one-stage meta-analysis using reconstructed survival data, Cox-based models, and restricted mean survival time (RMST). After screening 8,797 studies, 17 RCTs were selected, involving a total of 4,584 patients. Of these, 2,140 (46.7%) received GemCis. The majority (68.9%) were diagnosed with intrahepatic or extrahepatic cholangiocarcinoma, and 80% had metastatic disease at the time of treatment. The pooled median OS in the GemCis group was 11.6 months (95% CI 11.3–12.2 months). GemCis plus pembrolizumab (hazard ratio [HR] 0.99, 95% CI 0.98–0.99; p <0.001), GemCis plus durvalumab (HR 0.98, 95% CI 0.97–0.99; p = 0.015), GemCis plus S-1 (HR 0.97 95% CI 0.95–0.99; p <0.001), and GemCis plus nab-paclitaxel (HR 0.98, 95% CI 0.98–0.99; p <0.001) demonstrated superior OS compared with GemCis alone. These combinations also showed increases in RMST by +1.1, +2.5, +2.8, and +2.1 months, respectively. In terms of progression-free survival, GemCis with ICIs (HR 0.91, 95% CI 0.78–0.94; p <0.001), GemCis plus S-1 (HR 0.98, 95% CI 0.96–0.99; p = 0.003), and GemCis plus nab-paclitaxel (HR 0.98, 95% CI 0.97–0.99; p <0.001) also demonstrated superiority, with corresponding RMST increases of +0.7, +1.9, and +2.5 months, respectively. Despite incremental advancements, a breakthrough in advanced BTC treatment remains elusive. Further improvements in treatment efficacy may require biomarker identification to optimize combinational therapies for better patient selection. This study analyzed recent RCTs, including KEYNOTE-966, TOPAZ-1, NIFE, and SWOG 1815, involving 4,584 patients with advanced biliary tract cancer. A meta-analysis of 17 treatment arms, using reconstructed survival data, confirmed the modest survival benefit of GemCis plus ICIs, supporting its guideline adoption. The findings, however, highlight the need for biomarker identification and better patient selection.

22 April 2025 in Liver Transplantation
Verified
Journal Article
Closed access
ZLZhihao Li
Zhihao Li
OJOwen Jones
Owen Jones
FTFernanda Takamatsu
Fernanda Takamatsu
JSJennifer Stunguris
Jennifer Stunguris
CMChristian Tibor Josef Magyar
Christian Tibor Josef Magyar
BSBlayne A. Sayed
Blayne A. Sayed
Background: Although living donor liver transplantation (LDLT) is increasingly adopted for pediatric LT, there is limited data whether live donation extends benefits to patients from the time of listing. This study investigated the benefits of pediatric LDLT through an intention-to-treat analysis. Methods: Pediatric candidates listed between 2001-2023 at a single Canadian center were categorized as pLDLT (with a potential live donor) or pDDLT (without a live donor). The primary endpoint was overall survival from the time of listing. The secondary endpoint involved the waitlist outcomes described by the probabilities of receiving LT or waitlist dropout. Results: Among 474 candidates, 219 (46.2%) had potential live donors. The pLDLT group had a higher likelihood of receiving a LT (aHR 1.38, 95%CI:1.16-1.64) and lower risk of dying without a transplant (aHR 0.11, 95%CI:0.01-0.82) compared to the pDDLT group. Survival rates from the time of listing were significantly better in the pLDLT group at 1-(98.6% vs. 87.6%), 5-(96.6% vs. 84.4%), and 10-(96.6% vs. 83.1%) years. Having a potential live donor was linked to a 72% reduction in mortality risk (aHR 0.28, 95%CI:0.12-0.64). Although the number of patients listed annually increased over the study period, the waiting time for deceased donation shortened. This correlated with increased LDLT utilization, suggesting LDLT not only improved outcomes but shortened wait times even for pDDLT patients. Conclusion: Having a potential live donor is associated with substantial survival benefit. Pediatric programs offering LDLT can expand the donor pool and decrease the waiting time for DDLT, supporting the argument for making LDLT a standard for pediatric candidates. Export

16 April 2024 in Liver Transplantation
Verified
Journal Article
Closed access
OJOwen Jones
Owen Jones
MCMarco P.A.W. Claasen
Marco P.A.W. Claasen
TITommy Ivanics
Tommy Ivanics
WCWoo Jin Choi
Woo Jin Choi
FGFelipe Gavaria
Felipe Gavaria
GSGonzalo Sapisochin
Gonzalo Sapisochin
Living donor liver transplantation (LDLT) offers the opportunity to decrease waitlist time and mortality for patients with autoimmune liver disease (AILD), autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis. We compared the survival of patients with a potential living donor (pLDLT) on the waitlist versus no potential living donor (pDDLT) on an intention-to-treat basis. Our retrospective cohort study investigated adults with AILD listed for a liver transplant in our program between 2000 and 2021. The pLDLT group comprised recipients with a potential living donor. Otherwise, they were included in the pDDLT group. Intention-to-treat survival was assessed from the time of listing. Of the 533 patients included, 244 (43.8%) had a potential living donor. Waitlist dropout was higher for the pDDLT groups among all AILDs (pDDLT 85 [29.4%] vs. pLDLT 9 [3.7%], p < 0.001). The 1-, 3-, and 5-year intention-to-treat survival rates were higher for pLDLT versus pDDLT among all AILDs (95.7% vs. 78.1%, 89.0% vs. 70.1%, and 87.1% vs. 65.5%, p < 0.001). After adjusting for covariates, pLDLT was associated with a 38% reduction in the risk of death among the AILD cohort (HR: 0.62, 95% CI: 0.42–0.93 [p<0.05]), and 60% among the primary sclerosing cholangitis cohort (HR: 0.40, 95% CI: 0.22–0.74 [p0.9]). Our study suggests that having a potential living donor could decrease the risk of death in patients with primary sclerosing cholangitis on the waitlist. Importantly, the post-transplant outcomes in this population are similar between the LDLT and DDLT groups.

28 August 2024 in Liver Transplantation
Verified
Journal Article
Closed access
OJOwen Jones
Owen Jones
ZLZhihao Li
Zhihao Li
CMChristian Tibor Josef Magyar
Christian Tibor Josef Magyar
NGNicolas Goldaracena
Nicolas Goldaracena
BSBlayne A. Sayed
Blayne A. Sayed
GSGonzalo Sapisochin
Gonzalo Sapisochin
Objective: To identify and categorize non-medical barriers encountered by recipient, donors, and healthcare providers in the context of living-donor liver transplantation (LDLT). Background: Liver transplantation (LT) is vital for individuals with liver failure, yet high mortality rates on the transplant waitlist persist. LDLT was introduced to address deceased-donor organ shortages, however, its adoption varies widely across regions, prompting the need to explore barriers hindering its implementation. Methods: The scoping review employed inclusion and exclusion criteria to identify studies focusing on non-medical barriers to LDLT in both adult and pediatric populations. Qualitative, quantitative, and mixed-method studies were considered, covering the period from Jan-2005 to Feb-2023. The review’s search strategy was conducted in Ovid MEDLINE and Ovid EMBASE databases. Studies meeting the criteria were assessed for their characteristics and findings, which were synthesized into recipient, donor, and provider level barriers. Results: Among 2394 initially screened articles, 17 studies were eligible for inclusion. Recipient-level barriers encompassed systemic disparities in access, limited social support, immigration status and inadequate awareness of LDLT. Donor-level barriers involved surgery-related risks, recovery time concerns, financial burdens, and religious beliefs. Provider-level barriers highlighted institutional support inadequacies and specialized surgeon shortages. Conclusion: The scoping review underscores non-medical barriers to LDLT across recipient, donor, and provider levels. These barriers include socioeconomic disparities, information gaps, and inadequate institutional support. The findings underscore the need for comprehensive national efforts to raise awareness about LDLT and provide essential financial support. Export

1 February 1996 in Neuroscience Letters
Verified
Journal Article
Closed access
JEJames H Eubanks
James H Eubanks
JPJose L. Perez-Velazquez
Jose L. Perez-Velazquez
RKRobert G. Kerr
Robert G. Kerr
PCPeter Carlen
Peter Carlen
LMLinda R. Mills
Linda R. Mills
OJOwen T. Jones
Owen T. Jones

7 November 2026 in HPB
Verified
Journal Article
Closed access
CMChristian Tibor Josef Magyar
Christian Tibor Josef Magyar
LALaia Aceituno
Laia Aceituno
AZAnudari Zorigtbaatar
Anudari Zorigtbaatar
WCWoo Jin Choi
Woo Jin Choi
OJOwen Jones
Owen Jones
GSGonzalo Sapisochin
Gonzalo Sapisochin